scispace - formally typeset
M

Michel A. Duchosal

Researcher at University Hospital of Lausanne

Publications -  103
Citations -  13434

Michel A. Duchosal is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Transplantation & Nicotinamide phosphoribosyltransferase. The author has an hindex of 29, co-authored 93 publications receiving 11647 citations. Previous affiliations of Michel A. Duchosal include Scripps Research Institute & University of Lausanne.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

IFNα activates dormant haematopoietic stem cells in vivo

Marieke A.G. Essers, +6 more
- 16 Apr 2009 - 
TL;DR: It is shown that in response to treatment of mice with interferon-α (IFNα), HSCs efficiently exit G0 and enter an active cell cycle, raising the possibility for new applications of type I interferons to target cancer stem cells.
Journal ArticleDOI

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

Amina Haouala, +5 more
- 24 Feb 2011 - 
TL;DR: Several pharmacokinetic aspects yet remain insufficiently investigated for imatinib mesylate, dasatinib, and nilotinib and widely prescribed co-medications, including known inhibitors or inducers of cytochrome P450 or drug transporters are reviewed.
Journal ArticleDOI

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry

Amina Haouala, +9 more
- 15 Jul 2009 - 
TL;DR: This is the first broad-range LC-MS/MS assay covering the major currently in-use TKIs, an improvement over previous methods in terms of convenience, sensitivity, selectivity and throughput, and may contribute to filling the current knowledge gaps in the pharmacokinetics/pharmacodynamics relationships of the latest TKI developed after imatinib.